Showing results 1 to 20 of 22
next >
| Preview | Issue Date | Title / Name | Author(s) |
| Jul-2007 | Cancer services to be proud of in rural Australia: lessons learnt from the Clinical Oncological Society of Australia cancer service audit | Begbie, S.; Underhill, C.; Begbie, Stephen | |
| May-2009 | A couple with gastrointestinal stromal tumor (GIST) | Poursoltan, P.; Begbie, S.; Poursoltan, Pirooz; Begbie, Stephen | |
| Dec-2013 | Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial | Araujo, J. C.; Trudel, G. C.; Saad, F.; Armstrong, A. J.; Yu, E. Y.; Bellmunt, J.; Wilding, G.; McCaffrey, J.; Serrano, S. V.; Matveev, V. B.; Efstathiou, E.; Oudard, S.; Morris, M. J.; Goebell, P. J.; Heidenreich, A.; de Bono, J. S.; Begbie, S.; et. al; Begbie, Stephen | |
| Jun-2016 | Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial | Courneya, K. S.; Vardy, J. L.; O'Callaghan, C. J.; Friedenreich, C. M.; Campbell, K. L.; Prappavessis, H.; Crawford, J. J.; O'Brien, P.; Dhillon, H. M.; Jonker, D. J.; Chua, N. S.; Lupichuk, S.; Sanatani, M. S.; Gill, S.; Meyer, R. M.; Begbie, S.; Bonaventura, T.; Burge, M. E.; Turner, J.; Tu, D.; Booth, C. M.; Begbie, Stephen | |
| Jul-2019 | Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer | Davis, I. D.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenbuerg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S, G,; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Sweeney, C. J.; Begbie, Stephen | |
| 1996 | Is measurement of total body nitrogen (TBN) a useful predictor of chemotherapy (C/T) toxicity in breast cancer? | Aslani, A.; Begbie, S.; Smith, R. C.; Alle, B. J.; Begbie, Stephen | |
| Feb-1996 | A late complication of palliative stenting of malignant oesophageal obstruction | Begbie, S.; Briggs, G.; Levi, J.; Begbie, Stephen | |
| Oct-2009 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study | Ciuleanu, T.; Brodowicz, T.; Zielinski, C.; Kim, J. H.; Krzakowski, M.; Laack, E.; Wu, T-L; Bover, I.; Begbie, S.; Tzekova, V.; Cucevic, B.; Pereira, J. R.; Yang, S. H.; Madhavan, J.; Sugarman, K. P.; Peterson, P.; John, W. J.; Krejcy, K.; Belani, C. P.; Begbie, Stephen | |
| Jan-1993 | Maloprim-induced pulmonary eosinophilia | Begbie, S.; Burgess, K. R.; Begbie, Stephen | |
| Dec-2009 | Mapping oncology services in regional and rural Australia | Underhill, C.; Bartel, R.; Goldstein, D.; Snodgrass, H.; Begbie, S.; Yates, P.; White, K.; Jong, K.; Grogan, P.; Begbie, Stephen | |
| Sep-2014 | Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice | Woo, H. H.; Begbie, S.; Gogna, K.; Mainwaring, P. N.; Murphy, D. G.; Parnis, F.; Steer, C.; Davis, I. E.; Begbie, Stephen | |
| Sep-2023 | NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma | Sim, H. W.; Wachsmuth, L.; Barnes, E. H.; Yip, S.; Koh, E. S.; Hall, M.; Jennens, R.; Ashley, D. M.; Verhaak, R. G.; Heimberger, A. B.; Rosenthal, M. A.; Hovey, E. J.; Ellingson, B. M.; Tognela, A.; Gan, H. K.; Wheeler, H.; Back, M.; McDonald, K. L.; Long, A.; Cuff, K.; Begbie, S.; Gedye, C.; Mislang, A.; Le, Hien; Johnson, M. O.; Kong, B. Y.; Simes, J. R.; Lwin, Z.; Khasraw, M.; Begbie, Stephen | |
| Dec-2003 | Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial | Scheithauer, W.; McKendrick, J.; Begbie, S.; Borner, M.; Burns, W. I.; Burris, H. A.; Cassidy, J.; Jodrell, D.; Koralewski, P.; Levine, E. L.; Marschner, N.; Maroun, J.; Garcia-Alfonso, P.; Tujakowski, J.; Van Hazel, G.; Wong, A.; Zaluski, J.; Twelves, C.; Begbie, Stephen | |
| Sep-2021 | Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy | Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); Begbie, Stephen | |
| Jul-2020 | Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors | Desai, J.; Gan, H.; Barrow, C.; Jameson, M.; Atkinson, V.; Haydon, A.; Millward, M.; Begbie, S.; Brown, M.; Markman, B.; Patterson, W.; Hill, A.; Horvath, L.; Nagrial, A.; Richardson, G.; Jackson, C.; Friedlander, M.; Parente, P,; Tran, B.; Wang, L.; Chen, Y.; Tang, Z.; Huang, W.; Wu, J.; Zeng, D.; Luo, L.; Solomon, B.; Begbie, Stephen | |
| Feb-2025 | A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study). | Crumbaker, M.; Shekar, S.; Lawrence, M.G.; Goldstein, L. G.; Yam, A. O.; Downton, T.; Begbie, S.; Zielinski, R.; Fox, W.; Araiza, N.; Yousif, J.; Ratnayake, L.; Antonarakis, E. S.; Denmeade, S. R.; Joshua, A. M.; Begbie, Stephen; Fox, William | |
| Dec-2013 | Phase II Trial of Intravesical Gemcitabine and Biomarker Evaluation in Patients with Superficial Urothelial Carcinoma of the Bladder | de Souza, P.; Begbie, S.; Hovey, L.; Rashid, P.; Aslan, P.; Malouf, D.; Awad, N.; Clements, A.; Hadley, A.; Galettis, P.; O'Malley, L.; Melbourne, W.; Johnson, L.; Tran, K.; Lynch, W.; Begbie, Stephen; Rashid, Prem; Nader, Awad | |
| Feb-2024 | A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma | Conduit, C.; Davis, I. D.; Goh, J. C.; Kichenadasse, G.; Gurney, H.; Harris, C. A.; Pook, D.; Krieger, L.; Parnis, F.; Underhill, C.; Adams, D.; Roncolato, F.; Joshua, A.; Ferguson, T.; Prithviraj, P.; Morris, M.; Harrison, M.; Begbie, S.; Hovey, E.; George, M.; Liow, E. C.; Link, E. K.; McJannett, M.; Gedye, C.; Australian and New Zealans Urogental and Prostrate Cancer Trils Group (ANZUP); UNISoN Investigators; Begbie, Stephen | |
| Nov-2015 | A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial | Davidson, A; Veillard, A-S; Tognela, A.; Chan, M. M. K.; Hughes, B. G. M.; Boyer, M.; Briscoe, K.; Begbie, S.; Abdi, E.; Crombie, C.; Long, J.; Boyce, A.; Lewis, C. R.; Varma, S.; Broad, A.; Muljadi, M.; Chinchen, S.; Espinoza, D.; Coskinas, X.; Pavlakis, N.; Millward, M.; Stockler, M. R.; Australasian Lung cancer Trials Group ALTG; Briscoe, Karen; Begbie, Stephen | |
| Feb-2026 | Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304) | Inderjeeth, A-J.; Martin, A.J.; Zielinski, R.R.; Begbie, S.; Cheung, L.; Chowdhury, S.; Frydenberg, M.; Horvath, L.G.; Joshua, A.M.; Lawrence, N.J.; Marx, G.; McCaffrey, J.; McDermott, R.S.; McJannett, M.; North, S.A.; Parnis, F.; Parulekar, W.R.; Pook, D.W.; Reaume, M.N.; Sandhu, S.; Tan, A.; Tan, T.H.; Thomson, A.H.; Vera-Badillo, F.; Williams, S.G.; Thomas, H.; Yip, S.; Zhang, A.Y.; Chi, K.N.; Stockler, M.R.; Sweeney, C.J.; Davis, I.D.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.; Begbie, Stephen D. | |
